CClinicalTrials.gg
CompletedNCT02621671Updated Nov 6, 2017

Communicating Multiple Disease Risks

A Phase 1 interventional study of Cognitive interview and Survey in Healthy, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-06.

Sponsored by Washington University School of Medicine · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Apr 2015, registered Nov 2015).
Phase
Phase 1
Study type
Interventional
Enrollment
1,191
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Study summary

Epidemiology seeks to improve public health by identifying risk factors for cancer and other diseases and conveying that information to relevant audiences. The audience is presumed to understand and use that information to make appropriate decisions about lifestyle behaviors and medical treatments. Yet, even though a single risk factor can affect the risk of multiple health outcomes, this information is seldom communicated to people in a way that optimizes their understanding of the importance of engaging in a single healthy behavior. Providing individuals with the ability to understand how a single behavior (obtaining sufficient physical activity) could affect their risk of developing multiple diseases could foster a more coherent and meaningful picture of the behavior's importance in reducing health risks, increase motivation and intentions to engage in the behavior, and over time improve public health.

The proposed study translates epidemiological data about five diseases that cause significant morbidity and mortality (i.e., colon cancer, breast cancer (women), heart disease, diabetes, and stroke) into a visual display that conveys individualized risk estimates in a comprehensible, meaningful, and useful way to diverse lay audiences.

02

Conditions studied

  • Healthy

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,765 studies on the registry; 271 are open to participants now.

Of its 324 completed or terminated interventional studies of FDA-regulated products, 212 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 30-65 years of age
  • Able to read and communicate in English
  • Not meeting national guidelines for aerobic physical activity (at least 150 minutes per week of moderate intensity aerobic physical activity)

Exclusion criteria

Exclusion Criteria:

  • Less than 30 years of age
  • Older than 65 years of age
  • Not able to read and communicate in English
  • Meets national guidelines for aerobic physical activity (at least 150 minutes per week of moderate intensity aerobic physical activity)
05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,191 participants (actual)

Study arms

  • Experimental
    Arm 1: Cognitive Interviews

    * Participants will complete several survey items, view 1 of 8 disease risk pictures (selected at random), and then complete further survey questions. * Participants will then be recorded giving their opinions on the remaining 7 disease risk pictures which depict the hypothetical risk of disease. * The entire visit will take no more than 90 minutes with no follow-up. * The first 10-20 participants will be randomized to this arm.

    Behavioral: Cognitive interview · Other: Survey

  • Experimental
    Arm 2: Experimental survey

    * Participants will be randomly assigned by GfK's computer to one of the 12 experimental conditions. * After completing questions about information seeking and physical activity, the participants will read a short scenario that describes the purpose of a risk assessment tool and ask them to imagine that they had just entered their information into such a tool. * Participants will see whichever risk ladder corresponds to the experimental condition to which they were assigned. * The hypothetical display will be consistent with a display generated for an individual whose risk profile includes risk increasing and decreasing factors, but does not engage in the recommended amount of physical activity.

    Other: Survey

Interventions

  • BehavioralCognitive interview
  • OtherSurvey
06

What researchers measure

Primary outcomes

  1. Test eight images/visual displays that communicate risk estimates of five diseases associated with physical activity as measured by participants understanding of the images/visual displays

    Survey questions will assess participants' cognitive and affective risk perceptions, response efficacy, perceived severity and reaction to the visual displays, health literacy and numeracy. The quantitative data will be examined using descriptive statistics (e.g., frequencies, mean, median, mode, range, interquartile range, standard deviation) to evaluate whether a potential variability problem exists (e.g., restricted range) .

    Time frame: Completion of accrual for Arm 1 participants (estimated to be 1 year)

  2. Most effective combination of strategies in communicating multiple disease risk estimates (Arm 2 only)

    -Participants will be randomly assigned by computer to 1 of the 12 experimental conditions. After completing questions about information seeking and physical activity they will read a short scenario that describes the purpose of a risk assessment tool and asks them to imagine that they had just entered their information into such a tool. Participants will see whichever risk ladder corresponds to the experimental condition to which they were assigned. The hypothetical display will be consistent with a display generated for an individual whose risk profile includes risk increasing and decreasing factors, but does not engage in the recommended amount of physical activity. To increase feasibility for the display will show the risk of the diseases in the same order regardless of experimental condition. Participants will be allowed to view the display as long as they wish.

    Time frame: Completion of accrual for Arm 2 participants (estimated to be 1 year)

Secondary outcomes

  1. Time that it takes to complete the survey that accompanies the images (Arm 1 only)

    -Verify that there are no issues with comprehension or interpretation that can cause the survey to go longer than 20 minutes.

    Time frame: Completion of accrual for first Arm 1 participants (estimated to be 1 year)

07

Study locations

1 site
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02621671
Lead sponsor
Washington University School of Medicine
Responsible party
Sponsor
First posted
Dec 3, 2015
Start date
Apr 1, 2015
Primary completion
Jun 27, 2017
Completion
Jun 27, 2017
Last update
Nov 6, 2017

Study contacts

Erika Waters, Ph.D., M.P.H.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion